![A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC)]()
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC)Nazha, A.; Sekeres, M.; Komrokji, R.; Steensma, D.; Kantarjian, H.; Roboz, G.; Fenaux, P.; Prebet, T.; Azarnia, N.; Zbyszewski, P.; Fruchtman, S.; Santini, V.; Silverman, L.; Platzbecker, U.; Garcia-Manero, G. · Leukemia Research · 2017